205 related articles for article (PubMed ID: 21337725)
1. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry.
Furst DE; Pangan AL; Harrold LR; Chang H; Reed G; Kremer JM; Greenberg JD
Arthritis Care Res (Hoboken); 2011 Jun; 63(6):856-64. PubMed ID: 21337725
[TBL] [Abstract][Full Text] [Related]
2. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
England BR; Yun H; Chen L; Vanderbleek J; Michaud K; Mikuls TR; Curtis JR
Arthritis Care Res (Hoboken); 2023 Feb; 75(2):231-239. PubMed ID: 34338449
[TBL] [Abstract][Full Text] [Related]
3. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
4. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.
Ranganath VK; Maranian P; Elashoff DA; Woodworth T; Khanna D; Hahn T; Sarkisian C; Kremer JM; Furst DE; Paulus HE
Rheumatology (Oxford); 2013 Oct; 52(10):1809-17. PubMed ID: 23813577
[TBL] [Abstract][Full Text] [Related]
5. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.
Jawaheer D; Messing S; Reed G; Ranganath VK; Kremer JM; Louie JS; Khanna D; Greenberg JD; Furst DE
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1811-8. PubMed ID: 22730408
[TBL] [Abstract][Full Text] [Related]
6. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
7. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.
Curtis JR; Chen L; Harrold LR; Narongroeknawin P; Reed G; Solomon DH
Arthritis Care Res (Hoboken); 2010 Jan; 62(1):101-7. PubMed ID: 20191497
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.
Harrold LR; Reed GW; Shewade A; Magner R; Saunders KC; John A; Kremer JM; Greenberg JD
J Rheumatol; 2015 Jul; 42(7):1090-8. PubMed ID: 25934829
[TBL] [Abstract][Full Text] [Related]
9. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
10. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
11. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-ups and predictors of achieving treatment target.
Xiang Y; Wang Q; Li H; Duan X; Fang Y; Yang P; Li Q; Wu R; Huo Y; Shi X; Wu Z; Wang Y; Jiang N; Hsieh E; Li M; Tian X; Zeng X;
Int J Rheum Dis; 2020 Dec; 23(12):1719-1727. PubMed ID: 33034424
[TBL] [Abstract][Full Text] [Related]
12. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
[TBL] [Abstract][Full Text] [Related]
13. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.
Lee SW; Kim SY; Chang SH
BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089
[TBL] [Abstract][Full Text] [Related]
15. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
16. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
17. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
19. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
[TBL] [Abstract][Full Text] [Related]
20. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
